{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:20:54Z","timestamp":1777486854098,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00277-019-03657-3","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T13:04:20Z","timestamp":1553087060000},"page":"1457-1466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-8108","authenticated-orcid":false,"given":"Christina","family":"Hadjiaggelidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evdokia","family":"Mandala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthalia","family":"Yiannaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Markala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodora","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Gkastari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenia","family":"Verrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asimina","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlina","family":"Konstantinidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"3657_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ajh.23390","volume":"88","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV (2013) Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88:226\u2013235","journal-title":"Am J Hematol"},{"key":"3657_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335\u2013348","journal-title":"Nat Rev Cancer"},{"key":"3657_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","volume":"138","author":"G Pratt","year":"2007","unstructured":"Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563\u2013579","journal-title":"Br J Haematol"},{"key":"3657_CR4","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1038\/bcj.2015.49","volume":"5","author":"T Dosani","year":"2015","unstructured":"Dosani T, Carlsten M, Maric I, Landgren O (2015) The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J 5:e321","journal-title":"Blood Cancer J"},{"key":"3657_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.coi.2004.01.004","volume":"16","author":"Z Fehervari","year":"2004","unstructured":"Fehervari Z, Sakaguchi S (2004) Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol 16:203\u2013208","journal-title":"Curr Opin Immunol"},{"key":"3657_CR6","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00018-009-0026-2","volume":"66","author":"CJ Workman","year":"2009","unstructured":"Workman CJ, Szymcak-Workman AL, Collison LW, Pilai MR, DAA V (2009) The development and function of regulatory T cells. Cell Mol Life Sci 66:2603\u20132622","journal-title":"Cell Mol Life Sci"},{"key":"3657_CR7","doi-asserted-by":"publisher","unstructured":"Raja Muthu KR, Hajek R. Regulatory cells and multiple myeloma (2012) \n                    https:\/\/www.intechopen.com\n                    \n                   \/\n                    doi.org\n                    \n                   \/\n                    https:\/\/doi.org\/10.5772\/31207","DOI":"10.5772\/31207"},{"key":"3657_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057\u20131061","journal-title":"Science"},{"key":"3657_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25 regulatory T cells. Nat Immunol 4:330\u2013336","journal-title":"Nat Immunol"},{"key":"3657_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.coi.2008.04.008","volume":"20","author":"TJ Curiel","year":"2008","unstructured":"Curiel TJ (2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol 20:241\u2013246","journal-title":"Curr Opin Immunol"},{"key":"3657_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.coi.2007.02.004","volume":"19","author":"HY Wang","year":"2007","unstructured":"Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19:217\u2013223","journal-title":"Curr Opin Immunol"},{"key":"3657_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2249.1993.tb05943.x","volume":"92","author":"F Merico","year":"1993","unstructured":"Merico F, Bergui L, Gregoretti MG, Ghia P, Aimo G, Lindley IJD, Caligaris-Cappio F (1993) Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 92:27\u201331","journal-title":"Clin Exp Immunol"},{"key":"3657_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.autrev.2008.08.002","volume":"8","author":"A Cava La","year":"2008","unstructured":"La Cava A (2008) Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev 8:83\u201387","journal-title":"Autoimmun Rev"},{"key":"3657_CR14","doi-asserted-by":"publisher","first-page":"293479","DOI":"10.1155\/2012\/293479","volume":"2012","author":"WMT \u0392raga","year":"2012","unstructured":"\u0392raga WMT, Atanackovic D, Colleoni GWB (2012) The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol 2012:293479","journal-title":"Clin Dev Immunol"},{"key":"3657_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235\u2013238","journal-title":"Nature"},{"key":"3657_CR16","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","volume":"116","author":"K Noonan","year":"2010","unstructured":"Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I (2010) A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116:3554\u20133563","journal-title":"Blood"},{"key":"3657_CR17","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.20060468","volume":"203","author":"N Seddiki","year":"2006","unstructured":"Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B (2006) Expression of interleukin IL-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203:1693\u20131700","journal-title":"J Exp Med"},{"key":"3657_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1084\/jem.20060772","volume":"203","author":"W Liu","year":"2006","unstructured":"Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4(+) Treg cells. J Exp Med 203:1701\u20131711","journal-title":"J Exp Med"},{"key":"3657_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform criteria for multiple. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"3657_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","volume":"144","author":"S Feyler","year":"2009","unstructured":"Feyler S, von Lilienfeld-Toal M, Jarmin S, Lee Marles L, Rawstron A, Ashcroft AJ, Owen RG, Selby PJ, Cook G (2009) CD4(+)CD25(+)FoxP3(+) regulatory-T cells are increased whilst CD3(+)CD4(\u2212)CD8(\u2212)\u03b1\u03b2TCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144:686\u2013689","journal-title":"Br J Haematol"},{"key":"3657_CR21","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","volume":"107","author":"M Beyler","year":"2006","unstructured":"Beyler M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL (2006) In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107:3940\u20133949","journal-title":"Blood"},{"key":"3657_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","volume":"07","author":"RH Prabhala","year":"2006","unstructured":"Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 07:301\u2013304","journal-title":"Blood"},{"key":"3657_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.leukres.2010.11.010","volume":"35","author":"R Gupta","year":"2011","unstructured":"Gupta R, Ganeshan P, Hakim M, Verma R, Sharma A, Kumar L (2011) Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 35:874\u2013878","journal-title":"Leuk Res"},{"key":"3657_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033\u20131045","journal-title":"Cancer Immunol Immunother"},{"key":"3657_CR25","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3109\/10428194.2011.652106","volume":"53","author":"KR Muthu Raja","year":"2012","unstructured":"Muthu Raja KR, Kovarova L, Hajek R (2012) Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 53:1406\u20131408","journal-title":"Leuk Lymphoma"},{"key":"3657_CR26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3324\/haematol.2008.005017","volume":"94","author":"B Blanco","year":"2009","unstructured":"Blanco B, P\u00e9rez-Sim\u00f3n JA, S\u00e1nchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Coss\u00edo S, Hern\u00e1ndez-Campo P, D\u00edez-Campelo M, Herrero-Sanchez C, Rodriguez-Serrano C, Santamar\u00eda C, S\u00e1nchez-Guijo FM, Del Ca\u00f1izo C, San Miguel JF (2009) Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 94:975\u2013983","journal-title":"Haematologica"},{"key":"3657_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3324\/haematol.11897","volume":"93","author":"D Atanackovic","year":"2008","unstructured":"Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kroger N (2008) CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 93:423\u2013430","journal-title":"Haematologica"},{"key":"3657_CR28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood-2006-02-003996","volume":"108","author":"K Rezvani","year":"2006","unstructured":"Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108:1291\u20131297","journal-title":"Blood"},{"key":"3657_CR29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/bjc.2011.575","volume":"106","author":"K Giannopoulos","year":"2012","unstructured":"Giannopoulos K, Kameniska W, Dmoszynska A (2012) The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterization of immune status in multiple myeloma. \u0392r J Cancer 106:546\u2013552","journal-title":"\u0392r J Cancer"},{"key":"3657_CR30","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1182\/blood.V118.21.2870.2870","volume":"118","author":"KR Muthu Raja","year":"2011","unstructured":"Muthu Raja KR, Kovarova L, Kaisarova P, Bartonova J, Hajek R, Michalek J (2011) Regulatory T cells predicts progression in previously untreated myeloma patients and treatment by cyclophosphamide, thalidomide plus dexamethasone reduces regulatory T cells. Blood 118:2870","journal-title":"Blood"},{"key":"3657_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/156800910791054239","volume":"10","author":"AK Gandhi","year":"2010","unstructured":"Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P (2010) Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 10:155\u2013167","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03657-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:06:11Z","timestamp":1584576371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03657-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3657"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03657-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}